We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Perimenopausal Estrogen Replacement Therapy Study (PERT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01308814
First Posted: March 4, 2011
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Susan Girdler, PhD, University of North Carolina, Chapel Hill
February 28, 2011
March 4, 2011
April 6, 2017
August 22, 2017
August 22, 2017
October 2010
March 2016   (Final data collection date for primary outcome measure)
  • Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) [ Time Frame: Baseline, month 12 ]
    Change from pre-trial (baseline) to post-trial (month 12) in the Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D has a Range from 0-60, with higher scores indicating the presence of more symptomatology. A score of 16 or greater is indicative of clinically significant symptoms of depression.
  • Change in Psychiatric Diagnosis as Assessed by the Structured Clinical Interview for DSM Disorders I/NP [ Time Frame: Baseline and when prompted by CES-D score ]
  • Change in Stress Reactivity During Laboratory Session Including Trier Social Stress Test [ Time Frame: Baseline, month 12 ]
    Primary measures reflecting stress reactivity will consist of mean arterial pressure (MAP), vascular resistance index (VRI), plasma cortisol, and plasma IL-6. For each of these four measures, a delta score (change from rest to stress) will be calculated and then standardized as Z scores. The individual Z scores will then be averaged to yield a single Stress Reactivity profile measure (average z score) - a composite Z score reflecting magnitude of activation in the four primary stress-responsive pathways. This composite z score at baseline will be subtracted from the composite z score at 12 months to yield this outcome measure.
  • Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) [ Time Frame: Baseline, month 1, 2, 4, 6, 8, 10, 12 ]
  • Change in Psychiatric Diagnosis as Assessed by the Structured Clinical Interview for DSM Disorders I/NP [ Time Frame: Baseline and when prompted by CES-D score ]
  • Change in Stress Reactivity During Laboratory Session Including Trier Social Stress Test [ Time Frame: Baseline, month 6 and 12 ]
    Primary measures reflecting stress reactivity will consist of mean arterial pressure (MAP), vascular resistance index (VRI), plasma cortisol, and plasma IL-6. For each of these four measures, a delta score (change from rest to stress) will be calculated and then standardized as Z scores. The individual Z scores will then be averaged to yield a single Stress Reactivity profile measure - a composite score reflecting magnitude of activation in the four primary stress-responsive pathways.
Complete list of historical versions of study NCT01308814 on ClinicalTrials.gov Archive Site
  • Change in Functional Well-being as Assessed by the Medical Outcomes Study 36-item Short Form (SF-36) [ Time Frame: Baseline, month 12 ]
    The Medical Outcomes Study 36-item Short Form (SF-36) is a measure of functional well-being, including physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to emotional health problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. The range of this scale is 0-100, where higher scores indicates a more favorable health state.
  • Percentage Meeting Criteria for Metabolic Risk [Baseline and Month 12] [ Time Frame: Baseline, month 12 ]
    Subjects will be classified as having metabolic risk if they either meet standard criteria for the metabolic syndrome (based on 3 of 5 risk factors: elevated blood pressure, fasting triglycerides, fasting glucose, waist circumference and low HDL-cholesterol) or they exhibit insulin resistance based on the homeostatic model assessment (HOMA) to derive HOMA-IR based on fasting insulin and glucose levels using the equation: HOMA-IR = fasting glucose (mmol/L) × fasting insulin (μU/mL)/22.5
  • Change in Percentage of Brachial Artery Diameter [ Time Frame: Baseline, month 12 ]
    Change (from Baseline-to-12 Month) in flow mediated dilatation (FMD) test of the brachial artery, dilatation occurs following an acute increase in blood flow, induced by via circulatory arrest in the arm for a period of time. Measured using high resolution ultrasound, yielding a measure of endothelial-dependent vasodilatation. The increase in brachial arterial diameter as a consequence of reactive hyperemia is compared to the baseline diameter of the artery and expressed as a percentage of the baseline diameter (% FMD). Flow-mediated vasodilatation at each time point was calculated as diameter of the brachial artery under reactive hyperemia minus baseline diameter of the brachial artery. The change presented here is calculated as 12 month %FMD minus baseline month %FMD.
  • Change in Baroreceptor Sensitivity [ Time Frame: Baseline, month 12 ]

    A finometer noninvasive blood pressure devise (FMS) was used to collect a 10 minute recording of beat-to-beat blood pressure and pulse rate during spontaneous breathing under quiet recumbent conditions. baroreflex sensitivity was computed from the most stable 5-minute segment of this 10-minute period. Cross-spectral analysis was used to estimate the average transfer function modulus (i.e., gain) between systemic blood pressure oscillations and R-R interval oscillations in the frequency range of 0.07-0.14 Hz, also known as the low frequency band. The units of this baroreflex sensitivity (BRS) were msec/mmHg.

    The outcome presented here is the 12 month BRS minus baseline BRS.

  • Change in Functional Well-being as Assessed by the Medical Outcomes Study 36-item Short Form (SF-36) [ Time Frame: Baseline, month 6 and 12 ]
  • Change in Metabolic risk [ Time Frame: Baseline, month 6 and 12 ]
    Subjects will be classified as having metabolic risk if they either meet standard criteria for the metabolic syndrome (based on 3 of 5 risk factors: elevated blood pressure, fasting triglycerides, fasting glucose, waist circumference and low HDL-cholesterol) or they exhibit insulin resistance based on the derivation of an insulin sensitivity index (ISI0,120 < 61) following the standard oral glucose tolerance test
  • Change in Flow Mediated Vasodilatation [ Time Frame: Baseline, month 6 and 12 ]
    Flow mediated vasodilatation of the brachial artery in response to reactive hyperemia using high resolution ultrasound, yielding a measure of endothelial-dependent vasodilatation.
  • Change in Baroreceptor Sensitivity [ Time Frame: Baseline, month 6 and 12 ]
    Cardiac autonomic control via EKG measurement of HR and beat-to-beat changes in BP to assess baroreceptor sensitivity
Not Provided
Not Provided
 
Perimenopausal Estrogen Replacement Therapy Study
Depression, Estrogen Replacement, and Cardiovascular Health in the Perimenopause

Study Background and Objectives: In the U.S. the majority of heart disease deaths are in women, not men. Much of the gender disparity in CVD rates relate to the burden of CV risk in women after the menopause. Depression has been associated with an increased risk for CVD morbidity and mortality. Even histories of recurrent depression in euthymic individuals are associated with elevated CV risk. Understanding the depression-CVD link may have particular relevance for women since women experience depression at a rate twice that of men. Substantial convergent evidence indicates that ovarian failure (estrogen deprivation) is one likely mechanism contributing to both CVD and depression in women. The perimenopause, a time associated with a two-fold increase in rates of depression, may provide an ideal opportunity for studying the pathophysiology of CV risk and depression in women.

The primary objective of this study is to examine the prophylactic role of estradiol in the development of depressive symptoms and the progression of cardiovascular risk in perimenopausal women with or without histories of depression. The investigators predict that women susceptible to depression will be particularly vulnerable to the acceleration of CVD in the context of the perimenopause and, consequently, will show differentially greater benefit of estradiol treatment during the menopause transition for both indices of CV risk (e.g. inflammation, endothelial function, stress reactivity), as well as depressive symptoms.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Perimenopause
  • Menopause
  • Depression
  • Drug: Estradiol
    Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
    Other Name: Climara and Prometrium.
  • Drug: Placebo
    Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
  • Placebo Comparator: Placebo
    Placebo patches for 12 months and placebo pills for 12 days every 2 months.
    Intervention: Drug: Placebo
  • Experimental: Estradiol
    Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
    Intervention: Drug: Estradiol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
172
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • must be between 45 and 60 years of age
  • must be in the menopause transition (irregular/ absent menstrual cycles or hot flashes)
  • must be are medically healthy

Exclusion Criteria:

- currently taking antidepressant medication

Sexes Eligible for Study: Female
45 Years to 60 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01308814
10-0542
R01MH087619 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Susan Girdler, PhD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
National Institute of Mental Health (NIMH)
Principal Investigator: Susan Girdler, PH.D. UNC
University of North Carolina, Chapel Hill
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP